- 201-500 Employees
- Based in Heidelberg, Germany
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell bispecific antibody (TandAb) that completed Phase I clinical trial for the treatment of various CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma.
Most Recent Annual Report
2018 Annual Report
Affimed NV does not currently have any hardcopy reports on AnnualReports.co.uk. Click the button below to request a report when hardcopies become available.
Please fill out the form below and click "Place Order" to complete your order.
Older/Archived Annual Reports